Suscribirse

Objectively Measured Physical Activity and Symptoms Change in Knee Osteoarthritis - 26/04/16

Doi : 10.1016/j.amjmed.2015.12.029 
Shao-Hsien Liu, MPH a, , Jeffrey B. Driban, PhD b, Charles B. Eaton, MD c, d, Timothy E. McAlindon, MD b, Leslie R. Harrold, MD e, Kate L. Lapane, PhD f
a Clinical and Population Health Research Program, Graduate School of Biomedical Sciences, University of Massachusetts Medical School, Worcester, Mass 
b Division of Rheumatology, Tufts Medical Center, Boston, Mass 
c Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Pawtucket 
d Departments of Family Medicine and Epidemiology, Warren Alpert Medical School, School of Public Health, Brown University, Providence, RI 
e Departments of Medicine and Orthopedics, University of Massachusetts Medical School, Worcester, Mass 
f Division of Epidemiology of Chronic Diseases and Vulnerable Populations, Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Mass 

Requests for reprints should be addressed to Shao-Hsien Liu, MPH, Clinical and Population Health Research Program, Graduate School of Biomedical Sciences, University of Massachusetts Medical School, 368 Plantation St, Worcester, MA 01605.Clinical and Population Health Research ProgramGraduate School of Biomedical SciencesUniversity of Massachusetts Medical School368 Plantation StWorcesterMA01605

Abstract

Objective

The study objective was to quantify the association between daily physical activity measured by accelerometer and 1-year changes in symptoms among people with knee osteoarthritis.

Methods

Participants from the Osteoarthritis Initiative had knee radiographs and physical activity assessed using GT1M ActiGraph (Pensacola, FL) uniaxial accelerometers at the 48-month visit. Physical activity was calculated and categorized as tertiles of average daily minutes in light and moderate-to-vigorous activity. Outcomes were 1-year change in symptoms measured by Western Ontario and McMaster Universities scales, including pain, stiffness, and physical function. Adjusted multivariable linear models estimated the relationship between tertiles of light or moderate-to-vigorous physical activity and changes in knee symptoms.

Results

Among 1059 participants (55% were women; mean age, 66 ± 9 years), greater time in light activity was associated with a trend toward declined physical function (P = .01). Greater time in daily moderate-to-vigorous activity also was associated with declined physical function (P = .01) and increased pain (P = .08). None of these average changes in symptoms reached minimally important clinical differences. However, greater daily time in both activities was associated with a higher probability of worsening symptoms among persons with Kellgren–Lawrence grade 4 osteoarthritis.

Conclusions

Objectively measured daily activity was not associated with 1-year symptom improvements among community-dwelling adults with knee osteoarthritis. In those with advanced disease (Kellgren–Lawrence grade 4), greater daily minutes in physical activity were associated with worsening symptoms. How best to implement exercise regimens in persons with advanced knee osteoarthritis to reduce the deleterious impact on symptoms needs to be explored.

El texto completo de este artículo está disponible en PDF.

Keywords : Knee osteoarthritis, Patient-reported outcomes, Physical activity


Esquema


 Funding: This study was supported by the National Heart, Lung, and Blood Institute (Contract Number: HHSN268201000020C, Reference Number: BAA-NHLBI-AR1006). The Osteoarthritis Initiative (OAI) is a public-private partnership composed of 5 contracts (N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Pfizer, Inc, Novartis Pharmaceuticals Corp, Merck Research Laboratories, and GlaxoSmithKline. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. CBE is a principal investigator of an OAI site, and TEM is a co-principal investigator of the same site.
 Conflict of Interest: CBE has received grants and has served as a consultant to Pfizer. KLL has served as a consultant to Janssen and GlaxoSmithKline.
 Authorship: All authors had access to the data and played a role in writing this manuscript.


© 2016  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 129 - N° 5

P. 497 - mai 2016 Regresar al número
Artículo precedente Artículo precedente
  • Hypertrophic Cardiomyopathy as a Cause of Sudden Cardiac Death in the Young: A Meta-Analysis
  • Aditya J. Ullal, Ramy S. Abdelfattah, Euan A. Ashley, Victor F. Froelicher
| Artículo siguiente Artículo siguiente
  • Prognostic Impact of Myocardial Injury Related to Various Cardiac and Noncardiac Conditions
  • Laura Sarkisian, Lotte Saaby, Tina S. Poulsen, Oke Gerke, Susanne Hosbond, Nikolaj Jangaard, Axel C.P. Diederichsen, Kristian Thygesen, Hans Mickley

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.